Kepos Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Kepos Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,164	Closed	-$813K	–	208
2019 Q4	$813K	Hold	13,164	–	–	0.08%	160
2019 Q3	$791K	Sell	13,164 -6,832	-34%	-$508K	0.08%	146
2019 Q2	$1.69M	Hold	19,996	–	–	0.17%	122
2019 Q1	$1.91M	Hold	19,996	–	–	0.14%	166
2018 Q4	$1.42M	Hold	19,996	–	–	0.11%	177
2018 Q3	$1.71M	Buy	+19,996	New	+$2M	0.09%	183

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Kepos Capital's ENTA Position: Q1 2020 in Review

Kepos Capital sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 13,164 shares — an estimated $813K sold.

Kepos Capital first reported a position in ENTA in Q3 2018 and held it in 6 quarters. The position peaked at $1.91M in Q1 2019. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

Kepos Capital reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 13,164 Enanta Pharmaceuticals shares in Q1 2020, an estimated $813K.
Kepos Capital first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Kepos Capital's Enanta Pharmaceuticals position peaked at $1.91M in Q1 2019.
156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.